Left Menu
Development News Edition

Study reveals how exactly an investigational drug stops coronavirus

According to the findings published in the Journal of Biological Chemistry, remdesivir blocks a particular enzyme, RNA-dependent RNA polymerase, that is required for genome replication of the virus.

Devdiscourse News Desk | Alberta | Updated: 28-02-2020 09:59 IST | Created: 28-02-2020 09:43 IST
Study reveals how exactly an investigational drug stops coronavirus
Gilead has initiated two Phase III clinical trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.  Image Credit: ANI

The novel coronavirus outbreak, a new strain of previously unidentified coronavirus in humans is rapidly spreading around the world, claiming more than 2,700 lives in China alone. As of now, there is no specific cure or vaccine for the virus, however, an investigational new drug developed by US biotech firm Gilead Sciences is being evaluated for the treatment of novel coronavirus, aka COVID-19.

A team of academic and industry researchers from the University of Alberta and Gilead Sciences have published new findings about how Remdesivir actually works in coronavirus patients. The investigational drug has demonstrated a potential activity in animal models against the viral pathogens Middle-East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), which are also coronaviruses.

According to the new findings, remdesivir blocks a particular enzyme, i.e. RNA-dependent RNA polymerase required for genome replication of the virus. Once the drug is incorporated into the growing RNA chain, the virus can no longer replicate.

"Even if you know a drug works, it can be a red flag if you don't know how it works, " said Matthias Götte, a virologist and professor at the University of Alberta, Edmonton, who led the JBC study.

"We know the drug works against different coronaviruses, like MERS and SARS, and we know the novel coronavirus is very similar to SARS. So I would say I'm cautiously optimistic that the results our team found with remdesivir and MERS will be similar with COVID-19," he further added.

Götte said more than one drug will be needed to properly fight emerging diseases like COVID-19, as with HIV and hepatitis C virus infections. The team is now waiting for results from ongoing clinical trials with remdesivir, which are expected by the end of April 2020.

Following the U.S. Food and Drug Administration's (FDA) rapid review and acceptance of its investigational new drug (IND) filing, Gilead has initiated two Phase III clinical trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.

Gilead said on Thursday that the new clinical studies expand the ongoing research into remdesivir, which includes two clinical trials in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the United States led by the National Institute of Allergy and Infectious Diseases (NIAID).

Gilead's primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19, and this complementary array of studies helps to give us a more expansive breadth of data globally on the drug's profile in a short amount of time.

Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

Gilead developed remdesivir as a response to the 2014 West African Ebola virus epidemic. The investigational drug is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

The study published in the Journal of Biological Chemistry was funded by the Canadian Institutes of Health Research and the Alberta Ministry of Economic Development, Trade and Tourism.

Download The Devdiscourse News App for Latest News.


TRENDING

OPINION / BLOG / INTERVIEW

Globalization post-coronavirus to get a hit, self-sufficiency paradigm to rule

The massive scale of coronavirus outbreak, accompanied by uncertainty and fear, could lead to new behaviors and beliefs in the 21st-century population that is empowered with the internet....

Ayurveda for COVID 19: Professionals owe the responsibility to protect it from quacks and fake news

Indian Ayurveda professionals are lagging behind their foreign counterparts in handling quacks and protecting credentials of the Ayurveda at the time of COVID 19 pandemic. The professionals of Ayurveda cannot abjure the responsibility to co...

Education post-coronavirus: Schools to rush for more digitalization

Digital education would undoubtedly boom in the post-coronavirus world, supported by educational institutions that have discovered its efficiency during the crisis, but it is still not expected to outshine traditional classroom learning....

Videos

Latest News

Taiwan's stimulus response to virus could reach $33 bln-media

Taiwans economic stimulus response to the coronavirus outbreak could reach T1 trillion 33.09 billion, Taiwan media reported late on Tuesday citing Premier Su Tseng-chang. The government is already rolling out a T60 billion package to help t...

Advance payments to be made to transport contractors

Advance payments will be made to transport construction industry contractors to retain the workforce and ensure it is ready to quickly gear up to build projects which will be vital to New Zealands COVID-19 economic recovery, Transport Minis...

Decision time: quarantine spells dilemma for domestic workers in Latin America

When the Chilean government announced a total quarantine last week for the wealthy eastern areas of capital Santiago where cases of coronavirus were most prevalent, Maria De Leon, a 31-year-old nanny, was presented with an unenviable choice...

Mexico registers 1,215 coronavirus cases, 29 deaths - health ministry

Mexicos health ministry on Tuesday registered 1,215 cases of coronavirus in the country, up from 1,094 the day before.It also said 29 people died from the virus in Mexico, up from 28 a day earlier. ...

Give Feedback